Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.72 |
| ▸ | RXRB | P28702 | 6/20 | 0.72 |
| ▸ | RXRG | P48443 | 6/20 | 0.72 |
| ▸ | RARA | P10276 | 3/20 | 0.72 |
| ▸ | RARB | P10826 | 3/20 | 0.72 |
| ▸ | RARG | P13631 | 3/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24055013 | 0.95 | RXRA (0.65) | RXRARXRBRXRGRARARARB | |
| SCHEMBL12181011 | 0.89 | RXRA (0.88) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6901737 | 0.89 | RXRA (0.61) | RXRARXRBRXRGRARARARB | |
| SCHEMBL12427196 | 0.88 | RXRA (0.63) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6915712 | 0.87 | RXRA (0.72) | RXRARXRBRXRGRARARARB | |
| SCHEMBL7622797 | 0.86 | RXRA (0.55) | RXRARXRBRXRGRARARARB | |
| SCHEMBL31758293 | 0.86 | RXRA (0.73) | RXRARXRBRXRGRARARARB | |
| SCHEMBL2594347 | 0.86 | RXRA (0.73) | RXRARXRBRXRGRARARARB | |
| SCHEMBL20398874 | 0.85 | RXRA (0.60) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6274241 | 0.85 | RXRA (0.53) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008740-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DJ Therapeutics LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12338214-B2 | Bexarotene derivatives and their use in treating cancer | DJ Therapeutics LLC (US) | 2025-06-24 | — | — | US | disclosed |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DAWN SCIENTIFIC PHARMACEUTICALS, LLC | 2021-11-25 | — | — | US | disclosed |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DAWN SCIENTIFIC PHARMACEUTICALS, LLC | 2021-11-25 | — | — | US | disclosed |
| EP-3758694-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DJ Therapeutics LLC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-2536276-B1 | NOVEL BEXAROTENE ANALOGS | UNIV ARIZONA (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9174917-B2 | Bexarotene analogs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174917-B2 | Bexarotene analogs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2012-12-06 | — | — | US | disclosed |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2012-12-06 | — | — | US | disclosed |
| US-7572816-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572816-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060014800-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005011573-A2 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| US-5837725-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | RXRA 3/4885RXRB 2/4885RXRG 1/4885 |
| US-12338214-B2 | Bexarotene derivatives and their use in treating cancer | C3AR1, CXCR3, CCR7 | RXRA 9/4885RXRB 18/4885RXRG 8/4885 |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | ENPP2, XPA, CCR8 | RXRA 4/4885RXRB 13/4885RXRG 5/4885 |
| US-20060014800-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, MC1R | RXRA 334/4885RXRB 349/4885RXRG 366/4885 |
| US-20260008740-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | CXCR3, CCR6, CCR9 | RXRA 63/4885RXRB 76/4885RXRG 69/4885 |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | TBXA2R, ENPP2, CXCL8 | RXRA 14/4885RXRB 7/4885RXRG 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.